Selecting the right antibody discovery partner is one of the highest-stakes decisions a VP of R&D will make, directly shaping program timelines, IP ownership, and clinical outcomes. The criteria, trade-offs, and red flags that matter most when evaluating discovery CROs for complex therapeutic modalities are addressed here.
What are the most important criteria for evaluating an antibody discovery partner?
When assessing potential partners early on, it’s helpful to focus first on three foundational areas that tend to anchor most evaluations. These include the structure of intellectual property ownership and the clarity of rights, the freedom to operate (FTO) associated with the platform, and the quality of outputs—ideally demonstrated through downstream progression. Together, these elements are often treated as baseline requirements during partner assessment.
Beyond these essentials, a more nuanced evaluation can be achieved by considering two broader dimensions. The first is scientific fit, which reflects how well the platform’s capabilities align with your specific target and modality needs. The second is financial fit, encompassing the compatibility of cost structure, milestone design, and long-term economic considerations. Strong alignment across both scientific and financial dimensions generally supports smoother execution and increases the likelihood of a successful partnership.
How does company size change what I should prioritize in a discovery partner?
Your priorities in partner evaluation should shift based on your company’s size, funding stage, and pipeline maturity.
If you’re at a small biotech (fewer than 50 employees), you’ll likely need to stay closely focused on financial flexibility. In practice, this means prioritizing how well you can manage upfront and downstream costs, keeping royalty exposure under control, and ensuring you preserve optionality for future transactions. These factors can be just as important as the science, especially when resources are constrained and future strategic paths are still evolving.
| Company Profile | Primary Priority | Key Risk to Avoid |
|---|---|---|
| Small biotech (<50 employees) | Service cost, no royalties | Milestones that encumber exit |
| Mid-sized biotech (50-200) | Platform value + budget balance | Overcommitting on timeline |
| Large pharma (>200 employees) | IP ownership, platform depth | Residual royalty obligations |
If you’re part of a mid-sized biotech (around 50–200 employees), your role is often to balance competing priorities. You should aim to weigh platform quality and validation alongside budget considerations and execution timelines. Rather than over-optimizing for any single dimension, the goal is to maintain enough rigor on the science while ensuring the program remains feasible and can progress efficiently.
If you’re operating within a large pharma organization (more than 200 employees), your evaluation should place greater emphasis on robustness and long-term risk management. This typically means focusing on the depth and reliability of the platform, ensuring strong IP positioning and control, and carefully mitigating risk across the entire development lifecycle. At this scale, consistency and defensibility often matter more than short-term cost savings.
By framing your evaluation through the lens of your organization’s context, you can more clearly identify which trade-offs matter most and make decisions that better support your strategic objectives.
What is the difference between a fully human antibody and a humanized antibody, and why does it matter for partner selection?
Fully human antibodies carry 100% human sequence, generated in vivo through natural immune selection. Humanized antibodies are non-human sequences that have been engineered to reduce immunogenicity, but they retain residual non-human residues and carry the engineering trade-offs that come with that process. Understanding the structural differences between a fully human vs humanized monoclonal antibody is critical for assessing long-term clinical risk. The immunogenicity implication is direct: fully human sequences are inherently compatible with human immune tolerance, while humanized sequences carry residual risk that must be managed through additional characterization and clinical monitoring.
Harbour Mice® (transgenic mice engineered to produce fully human antibodies in both a conventional H2L2 format and a heavy-chain-only HCAb format) generate antibodies through natural affinity maturation, not post-hoc engineering. The industry shift toward fully human platforms is accelerating, driven by the goal of reducing humanization costs and timelines that were standard with earlier-generation transgenic mouse platforms.
Is a fully-human HCAb VH the same as a VHH nanobody? I keep seeing these terms used interchangeably.
Fully-human HCAb VHs and VHH nanobodies are structurally related but scientifically distinct, and equating them is one of the most common terminology errors in the field. VHH nanobodies are single-domain antibody fragments derived from camelid heavy-chain-only antibodies. HCAbs produced by Harbour Mice® are fully human heavy-chain-only antibodies, meaning their variable domains (VH) carry 100% human germline sequence rather than camelid sequence.
This distinction has direct clinical and IP consequences. Camelid-derived VHH sequences require humanization before clinical use, reintroducing the engineering trade-offs described above. Fully human HCAb-derived VH domains do not. When evaluating a partner’s single-domain or heavy-chain antibody offering, confirm explicitly whether the sequences are of human or camelid origin.
When should I choose a partner with HCAb capability over a conventional H2L2 platform?
HCAb-derived binders are the preferred starting format for bispecific and multispecific antibody programs, and for next-generation ADC formats where molecular size is a design constraint. The core reason is chain mispairing: conventional bispecific antibody manufacturing using two full IgG molecules requires engineering solutions to prevent incorrect heavy-light chain combinations, adding complexity, cost, and yield risk. HCAb-derived binders eliminate the light chain entirely, removing the mispairing problem at the molecular level.
For ADC applications, single-domain antibodies derived from HCAb technology enable payload titration and, for constructs below approximately 40 kDa total molecular weight, can achieve renal clearance, a pharmacokinetic profile not accessible with full-length IgG. Emerging formats including bispecific ADCs and antibody fragment ADCs are driving demand for HCAb capability specifically. A partner without a validated HCAb platform will be unable to support these modalities without outsourcing the critical discovery step.
For standard monoclonal antibody programs against conventional targets, a well-validated H2L2 platform with robust screening is sufficient. The decision point is modality complexity, not target class alone.
What screening technologies should I expect a best-in-class discovery partner to offer?
Single B-cell (SBC) cloning has become the benchmark for high-throughput antibody discovery, compressing the screening timeline to approximately one month compared to two to three months for traditional hybridoma methods. A partner operating only hybridoma workflows will be structurally slower on timeline-sensitive programs. Next-generation sequencing (NGS) integrated with in vivo immunization technologies is also now a standard expectation for deep repertoire coverage.
If you’re evaluating a potential partner, you’ll likely find yourself asking whether they also offer phage display or yeast display—and it’s a worthwhile question to raise. Both are well-established in vitro library methods, known for providing large sequence diversity and for their widespread use across the industry, making them important reference points when comparing platform capabilities. The important distinction is that phage display and yeast display work from synthetic or semi-synthetic human sequence libraries, whereas in vivo transgenic mouse platforms such as Harbour Mice® generate antibodies through natural affinity maturation inside a living immune system. This biological selection process tends to produce leads with superior developability profiles, higher solubility, better thermal stability, and nanomolar affinity, without requiring the extensive post-selection engineering that in vitro display hits often need. A best-in-class partner will be conversant in all three approaches and able to recommend the right method based on your target class, epitope requirements, and modality.
Beyond throughput, functional screening capability is the differentiator for complex modalities. Platforms that provide a functional readout in a mammalian system at library scale, rather than binding-only data, allow earlier identification of leads with the right mechanism of action. When evaluating a partner, ask specifically whether their screening platforms generate binding data alone or functional activity data, and at what throughput.
How do I evaluate a partner’s IP model, and what terms should I insist on?
As you evaluate potential partners, you should treat full IP ownership of any antibodies discovered through their platform as a baseline requirement rather than a point of negotiation. In most cases, you’ll want to ensure that your organization retains complete ownership of all sequences, constructs, and data generated during the collaboration, as this is broadly considered standard practice.
You should also pay close attention to how the partner structures downstream economics. Royalty obligations on future commercial sales are among the most common sticking points, and in many cases, they may become a deal-breaker—particularly if you’re at a smaller company. In those settings, downstream milestones and royalties can directly impact investor expectations and long-term value capture, making it critical to address these terms early in the evaluation process.
Freedom to Operate (FTO) is a separate but equally critical dimension. A partner whose platform sits under third-party IP constraints can create freedom-to-operate problems for your program even if they grant you sequence ownership. Confirm that the partner holds clean, independently controlled IP on their transgenic mouse platform and screening technologies. Nona Biosciences’ model grants clients full IP ownership and complete FTO, with no royalties on discovered antibodies, which is a structural differentiator relative to platforms that carry licensing obligations from upstream IP holders.
What clinical validation signals should I look for when assessing a partner’s track record?
The most credible validation signals are clinical-stage molecules originating from the partner’s platform, not just discovery programs completed. Nona Biosciences has completed 300+ antibody discovery programs and has 19+ clinical-stage molecules derived from its platforms, including the Pfizer MesoC2 ADC program presented at ASCO in Phase 1. Strategic collaborations with large pharma, such as Nona’s collaboration with AstraZeneca, provide additional evidence of platform credibility at institutional due-diligence standards.
When a partner cites program counts, ask for the breakdown by modality and clinical stage. A high number of discovery programs with few clinical-stage molecules may indicate a platform that generates leads but does not support them through to IND-enabling studies. The relevant metric for a VP of R&D is molecules in the clinic, not molecules in the freezer.
What is the difference between a consultative discovery partner and an execution CRO, and which do I need?
An execution CRO operates as a menu-driven service provider: you specify the assay, they run it. A consultative partner is invested in program outcome and will adapt strategy based on emerging data, flag risks proactively, and recommend modality or format changes when the science warrants it. The distinction matters most for complex or novel targets where the discovery path is not predetermined.
For straightforward targets with established precedent, an execution CRO may be sufficient and cost-effective. For programs involving novel targets, difficult antigens, or complex modalities such as bispecific ADCs or in vivo CAR-T, a consultative partner with deep modality expertise reduces the risk of late-stage failures that trace back to early discovery decisions. The question to ask during partner evaluation is: “Can you show me a case where you changed the recommended approach mid-program based on data, and what was the outcome?”
What does an integrated end-to-end discovery partner offer that a specialist CRO cannot?
An integrated partner covers the full spectrum from target validation through IND filing under a single operational framework, eliminating the handoff risk that accumulates when multiple specialist CROs are coordinated in sequence. I-to-I® (Nona’s integrated end-to-end service pathway from ideation through IND filing) spans antigen preparation, immunization, screening, lead generation, antibody engineering, developability assessment, CMC, and toxicology within one organization.
The practical advantage is data continuity: every decision made in early discovery is visible to the teams running later-stage studies, reducing the reformulation and re-characterization work that typically occurs at CRO transitions. For VPs of R&D managing lean internal teams, this also reduces the project management overhead of coordinating multiple vendor relationships across a single program. Explore I-to-I® for a detailed view of how each stage connects operationally.
If your program involves bispecific antibodies, ADCs, or complex multispecific formats and you are evaluating discovery partners, speak directly with Nona’s scientific team about your target profile and modality requirements. Nona’s scientists will assess platform fit and provide a transparent view of timelines, IP terms, and relevant case studies before any commercial discussion begins.
- J. Maynard et al., Antibody engineering, Annual Review of Biomedical Engineering, 2000. Link
- R. Kontermann et al., Bispecific antibodies, Drug Discovery Today, 2015. Link
- C. Spiess et al., Alternative molecular formats and therapeutic applications for bispecific antibodies, Molecular Immunology, 2015. Link
- J. Xu et al., Diversity in the CDR3 region of VH is sufficient for most antibody specificities, Immunity, 2000. Link
- A. Beck et al., Strategies and challenges for the next generation of antibody-drug conjugates, Nature Reviews Drug Discovery, 2017. Link
- P. Carter et al., Bispecific human IgG by design, Journal of Immunological Methods, 2001. Link
- H. Kaplon et al., Antibodies to watch in 2024, mAbs, 2024. Link
